Isogen LLC, a sterile manufacturer based in Wilmington, DE, has made several appointments to its management team.

Mark Koscinski, CPA, has been appointed chief financial officer and treasurer of Isogen, and is responsible for the overall financial strength and stability of the Company. Mr. Koscinski serves as the principal financial and accounting officer of the company, with oversight of the treasury and controllership functions. Mr. Koscinski has more than 25 years of experience in finance, with more than 15 years in executive leadership. Prior to joining Isogen, Mr. Koscinski was Senior vice president and chief financial officer of Butler International, a $350 million technical services business. Mr. Koscinski was also manager at KPMG and has significant SEC experience.

Rosemarie Fisher, CPA, has been appointed controller. Ms. Fisher’s responsibilities include improving Isogen’s profitability by accessing a wide range of areas from budgets and performance measurements to accounting and reporting systems. Currently, Ms. Fisher is president of Real Possibilities, a management and technology firm, and serves Isogen through this company. Prior to founding Real Possibilities, she held the positions of executive vice president and chief financial officer at Pyramid Consulting, general accounting manager at The Hibbert Group and corporate accounting officer at Tingley Rubber Corporation.

Diane Wood has been appointed director, Quality Assurance and Regulatory Affairs. In her role, She is responsible for the planned and systematic compliance activities necessary to ensure all products and services Isogen provides to its customers meet the given requirements. A senior quality executive, Ms. Wood has more than 25 years’ experience in developing quality and documentation systems and authoring multiple CMC filings and biologic applications. Prior to joining Isogen, Ms. Wood was a quality leader at Beecham Laboratories, Hoechst-Roussel Pharmaceuticals, Ortho Pharmaceuticals / Advanced Care Products, Novo Nordisk Pharmaceuticals and Serono Laboratories.

Malcolm Montgomery, Ph.D., has been appointed director, Lab Services. He will lead Isogen’s Lab Services team in analytical method development/validation and the testing/release of pharmaceutical products. Dr. Montgomery is an analytical chemist with more than 15 years of experience in small molecule and biological drug products. Prior to joining Isogen, Dr. Montgomery held director and senior level positions at Microbac Laboratories, Centocor Research and Development, Merck, Apollon and Wyeth-Ayerst.

Robin Uhl has been appointed director of Business Development. Working closely with the chief executive officer, Ms. Uhl is responsible for generating revenue, building a strong sales pipeline, creating awareness of Isogen in the marketplace and developing partnerships that will propel Isogen’s growth. Ms. Uhl has more than 20 years of experience in leading marketing, communications and sales for professional services firms. Prior to joining Isogen, Ms. Uhl served as vice president of marketing for Butler International. In addition, Ms. Uhl has held key positions at Arthur Andersen and Dun and Bradstreet.

“We’re very excited about the management team we have in place at Isogen. All of our directors — those added recently, as well as those who have been with us from the start — are sought-after leaders who are at the top of their game. We truly have a winning team,” commented Austin McDonald, Isogen’s chief operating officer.